Providing a seamless patient experience from first image-based detection through survivorship
Azra AI, an end-to-end platform that automates workflows and coordinates care in oncology and critical service lines, and Riverain Technologies, specialists in AI-powered ling imaging, have collaborated to provide a seamless patient experience from first image-based detection through survivorship.
Deaths from lung cancer are often due to patients falling through the cracks between detection and treatment. This collaboration hopes to close the gaps by integrating Riverain's ClearRead imaging solutions with Azra AI's real-time pathology and radiology analysis, automated care coordination, and survivorship management.
The companies will provide a solution that combines image detection of solid, sub-solid, and ground-glass nodules, radiology and pathology reports, navigation, and advanced analytics into a single, connected ecosystem.
Integrating AI findings into a solution and extending advanced analytics across the continuum enables Riverain and Azra AI to minimise the divide between radiology, pulmonology, and oncology, resulting in health systems accelerating diagnosis, reducing time to treatment, and supporting patients through every phase of their cancer journey.
John Marshall, CEO of Azra AI, said, “Together, Azra AI and Riverain are ensuring that lung cancer patients don’t just get detected, they get connected to care faster and supported across their entire journey. This partnership creates true end-to-end visibility, empowering providers to deliver better clinical outcomes while strengthening health system performance.”
Steve Worrell, CEO of Riverain Technologies, said, “Riverain has always helped radiologists see clearly so they can save lives. Partnering with Azra AI extends that clarity beyond the scan, uniting two leaders to give health systems a tailored, robust plan for the entire continuum of lung cancer care, not just another set of products.”
